Intervening to Repair Cognitive and Behavioural Problems in Adults Exposed to Childhood Malnutrition

NCT ID: NCT04053218

Last Updated: 2019-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-15

Study Completion Date

2020-12-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Globally, in 2011, 52 million children under 5 years old suffered from acute malnutrition, and a further 165 million children showed evidence of chronic undernutrition or stunting. It was also estimated that 3.1 million children died in 2011 of malnutrition related causes. The survivors, due to deprivation of critical nutrients in the most important period of development and growth, are left with permanent damage, including an increased risk of cardio-metabolic disease, poorer educational achievement and diminished earning potential.

In Jamaica in 2012, 2.5% of children were moderately or severely underweight (more than two standard deviations below weight-for-age by international reference populations), falling from as high as 8.9% in 1993. Though there have been modest reductions in the incidence of acute malnutrition in Jamaica over the past 20 years, the risk remains high in poor families and among children who are being weaned. Hence, the problem is an ongoing one and we have a significant pool of survivors of childhood malnutrition who have now reached adulthood and face the consequences of early nutrient deprivation.

The brain is particularly vulnerable to the effects of malnutrition and studies have demonstrated both structural (brain atrophy) and functional (cognitive impairment and poor academic achievement) changes. This evidence, however, has been mainly in later childhood and adolescence. In addition, there is local data that suggests that cardio-metabolic risk factors are increased in these adult survivors, which are well-described precursors of cerebrovascular disease and cognitive impairment. Therefore, in adulthood there may be accelerated cognitive decline due to a poor cardio-metabolic profile superimposed on pre-existing brain injury.

We hypothesise that there are differences in cognitive function (poorer memory and executive function)and emotional responses in adult survivors of childhood malnutrition compared to those not exposed to early childhood malnutrition.

There is evidence suggesting that aerobic exercise and omega-3 supplementation have some benefit in reversing cognitive decline in older adults, but they have not been investigated in survivors of childhood malnutrition.Hence, we propose to introduce a six month intervention of supervised aerobic exercise and omega-3 supplementation, and will compare cognitive function pre and post intervention/placebo between malnutrition survivors and controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will assess anthropometry, cardio metabolic profiles, cognitive and emotional domains between adult survivors of severe acute malnutrition (SAM) in childhood and healthy controls from similar communities, pre and post a six month intervention of supervised aerobic exercise and omega-3 supplementation.

Recruitment: The cases will include adult SAM survivors admitted to the University Hospital of the West Indies (UHWI) now between 20 and 55 years. They have been identified from UHWI records and traced using last known addresses by experienced field workers. Community controls will be recruited from the same communities, one per case and matched for sex, and age (within 5 years).

Sample Size Calculations: These are based on assessing differences in cognitive function using the NIH (National Institutes of Health) Toolbox Cognitive battery as the primary outcome measure between SAM survivors and community controls, and between pre-and post-intervention groups.

Using a test at the 5% level of statistical significance we will have 80% power to detect a difference of 2.8 √(2/n) standard deviations between cases and controls, where n=number of cases.

Therefore, at n=50, difference= 2.8 √ (2/50) = 0.56 SD

For the NIH Toolbox, raw scores are converted to a normalized score, where 100 is equivalent to the normative mean for the relevant age/education stratification, and 15 units corresponds to 1 standard deviation (SD).

For n=50, 0.56 x 15 = 8.4 units. So, using a test at the 5% level of statistical significance we will have 80% power to detect a difference of 8.4 units between the two groups. Meta-analyses on intervention studies of cognitive changes with aerobic exercise have shown a medium effect size of approximately 0.48-0.57, (154) which corresponds to 7.2-8.5 units. Hence, using 50 subjects per group will provide an adequate sample size.

Standard Operating Procedures:

After obtaining informed written consent, all baseline data will be collected by one of two trained researchers over one to two visits. These tests will be repeated after the six-month intervention.

Details of Methods to be used:

Anthropometry: Height and weight will be measured with subjects without shoes and in light clothing to calculate body mass index (BMI, kg/m2). Weight will be measured to the nearest 0.1kg. Height will be measured to the nearest 0.1cm.

Dual-energy X-ray absorption (DXA) (Model General Electric Lunar Prodigy) will be used to measure total and regional percent (%) body fat, fat mass, lean tissue mass, and bone mineral content.

Blood Pressure: Participants will be rested for \>10 minutes seated in a temperature controlled environment. Blood pressure will be measured three times on the right arm using an automatic blood pressure monitor with at least 30 seconds in between each reading. The three measurements will be averaged for analysis. The mid upper arm circumference will be measured to determine the appropriate sized blood pressure cuff.

Fitness Testing: Subjects will exercise to voluntary exhaustion during a treadmill test using a modified Bruce protocol. Oxygen consumption, carbon dioxide production, and minute ventilation will be measured breath-by-breath using a metabolic cart and the average of the final three 20 second values of oxygen consumption will be the maximum rate of oxygen consumption.

Cognitive Tests: The NIH Toolbox, a computerised, neurocognitive test battery will be used to assess cognitive and emotion domains. In the cognitive domain, this study will assess executive function, cognitive flexibility, inhibitory control, attention, episodic memory, working memory and processing speed.

For the emotion domain, we will use a self-report battery and test four central subdomains including psychological well-being, social relationships, stress and self-efficacy and negative affect.

Blood Tests: 30 millilitres of blood will be taken in the fasted state for assessment of plasma levels of insulin and glucose, lipids, brain-derived neurotrophic factor, insulin-like growth factor and omega-3 fatty acid profile in erythrocytes. A full oral glucose tolerance test will be done with samples for glucose and insulin at 30 minutes, 60 minutes, 90 minutes and 120 minutes after 75 grams glucose orally.

Data Analysis:

Descriptive data will be provided calculated for all variables. Multiple linear regression analysis will be used to determine if there are any differences in outcome variables between survivors and controls. These analyses will be controlled for potential confounding variables such as age, sex and socio-economic status. The size of effects will be assessed as the regression coefficient for a binary treatment variable. Change in cognitive outcomes will be assessed by including the baseline measure of cognitive function as a predictor. Interaction tests will be used to assess whether any treatment effect differs by baseline cognitive function, age, sex and socio-economic status.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Acute Malnutrition Cognitive Impairment Emotional Disturbances

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Participants will be enrolled in one of two groups, exercise and omega-3 supplementation or placebo group. Subjects and controls in the first group will receive supervised aerobic exercise on a treadmill, targeting 75-85% heart rate reserve for 45 minutes per session, three days per week. Each participant's heart rate reserve will be calculated using the formula: Heart rate reserve=maximal heart rate - resting heart rate. Each participant in this group will also receive an omega-3 supplement containing 2 grams /day.

The placebo group will receive 2 grams of olive oil (mainly oleic acid, a monounsaturated fatty acid) and standardised health education, face-to-face and written (American Heart Association educational materials), including recommendations for regular physical activity and nutrition.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
The participant will be unaware of whether the capsules are supplement or placebo. The investigators will know that all persons in the exercise group will receive omega-3 supplements and that those not exercising will be receiving placebo capsules.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exercise and supplement

Supervised aerobic exercise three times weekly and daily omega-3 supplements

Group Type ACTIVE_COMPARATOR

Exercise plus omega-3 supplement

Intervention Type COMBINATION_PRODUCT

Supervised aerobic exercise and omega-3 supplement

Placebo

Olive oil capsules. No supervised exercise but written recommendations for daily physical activity from the American Heart Association

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Olive oil placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise plus omega-3 supplement

Supervised aerobic exercise and omega-3 supplement

Intervention Type COMBINATION_PRODUCT

Placebo

Olive oil placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* SAM survivors, both males and females and between the ages of 20 and 50 years
* Community controls will be identified from the same street address as the cases and matched for sex, age ±5 years.

Exclusion Criteria

* Pregnancy
* Unstable angina or myocardial infarction diagnosed within 3 months;
* Heart failure (New York Heart Association category 2) or significant valvular dysfunction;
* Peripheral arterial disease with claudication, major orthopaedic, chronic pain, or neuromuscular disorders restricting exercise;
* Pulmonary or renal failure;
* Poorly controlled hypertension (\>190/110 mmHg) on two separate occasions, or type 2 diabetes mellitus, or type 1 diabetes mellitus regardless of control;
* Recent hospitalisation for severe disease or surgery;
* Regularly exercises at moderate or vigorous intensity for more than 30 minutes three times or more per week;
* Is currently taking daily omega-3 supplements for over two weeks.
Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of The West Indies

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Terrence E Forrester, DM, PhD

Role: PRINCIPAL_INVESTIGATOR

University of the West Indies, Mona Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of the West Indies

Kingston, , Jamaica

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Jamaica

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dean, Faculty of Medicine

Role: CONTACT

876-927-1289

Terrence E Forrester, DM, PhD

Role: CONTACT

876-977-6803

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Terrence Forrester, PhD

Role: primary

876-977-6803

Michael S Boyne, PhD

Role: backup

876-927-1621

References

Explore related publications, articles, or registry entries linked to this study.

Francis-Emmanuel PM, Thompson DS, Barnett AT, Osmond C, Byrne CD, Hanson MA, Gluckman PD, Forrester TE, Boyne MS. Glucose metabolism in adult survivors of severe acute malnutrition. J Clin Endocrinol Metab. 2014 Jun;99(6):2233-40. doi: 10.1210/jc.2013-3511. Epub 2014 Feb 11.

Reference Type BACKGROUND
PMID: 24517147 (View on PubMed)

Tennant IA, Barnett AT, Thompson DS, Kips J, Boyne MS, Chung EE, Chung AP, Osmond C, Hanson MA, Gluckman PD, Segers P, Cruickshank JK, Forrester TE. Impaired cardiovascular structure and function in adult survivors of severe acute malnutrition. Hypertension. 2014 Sep;64(3):664-71. doi: 10.1161/HYPERTENSIONAHA.114.03230. Epub 2014 Jun 30.

Reference Type BACKGROUND
PMID: 24980666 (View on PubMed)

Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005381. doi: 10.1002/14651858.CD005381.pub3.

Reference Type BACKGROUND
PMID: 18646126 (View on PubMed)

Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M, Uauy R. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. J Nutr Health Aging. 2009 Mar;13(3):198-202. doi: 10.1007/s12603-009-0057-2.

Reference Type BACKGROUND
PMID: 19262951 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ECP235,15/16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omega-3 Supplementation and Behavior Problems
NCT02334098 COMPLETED PHASE2/PHASE3